Research progress in antibody drug therapy for relapsed/refractory diffuse large B-cell lymphoma

Yanyan SUN; Weichen ZHAO; Chunyuan HE; Yimiao XIA; Wei ZHOU; Yuanyuan ZHEN; Junjie JIANG; Facai WANG

Return

Research progress in antibody drug therapy for relapsed/refractory diffuse large B-cell lymphoma

VernacularTitle:抗体药物治疗复发/难治性弥漫性大B细胞淋巴瘤的研究进展
Author: Yanyan SUN ¹ ; Weichen ZHAO ¹ ; Chunyuan HE ¹ ; Yimiao XIA ¹ ; Wei ZHOU ¹ ; Yuanyuan ZHEN ¹ ; Junjie JIANG ¹ ; Facai WANG ¹
Author Information

1. Dept. of Pharmacy，Lu’an Hospital of Anhui Medical University （Lu’an People’s Hospital），Anhui Lu’an 237005，China
Publication Type:Journal Article
Keywords: relapsed/refractory diffuse large B-cell lymphoma; monoclonal antibodies; bispecific antibodies; antibody-drug
From: China Pharmacy 2025;36(13):1677-1682
CountryChina
Language:Chinese
Abstract: Diffuse large B-cell lymphoma （DLBCL） is a highly heterogeneous disease. Although standard first-line regimens can cure ＞50% of patients， approximately one-third of them develop relapsed/refractory DLBCL （r/r DLBCL）. Consequently， immunotherapy targeting molecular abnormalities has become pivotal for managing r/r DLBCL. The results of this review show that with advances in understanding DLBCL pathogenesis and the tumor immune microenvironment， antibody-based therapies have evolved rapidly， progressing from monoclonal antibodies （e.g.， rituximab， tafasitamab） to bispecific antibodies（e.g.， odronextamab，glofitamab， epcoritamab） and antibody-drug conjugate （e.g.， polatuzumab vedotin， loncastuximab tesirine）. These engineered agents enhance immune cytotoxicity and tumor-specific targeting， providing novel therapeutic options for r/r DLBCL patients.